Journal profile · Multiple
Hematology Transfusion and Cell Therapy
ISSN 2531-1379 · Elsevier · Spain
Hematology Transfusion and Cell Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.5 (journal website); diamond open access (no APC); no APC; median 182 days to acceptance (109 articles, last 24 months); 2,397 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Hematology Transfusion and Cell Therapy is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hemoglobinopathies and Related Disorders, Acute Myeloid Leukemia Research and Blood donation and transfusion practices, together about 24.9% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Hematology, Transfusion and Cell Therapy is a quarterly scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), Associazione Italo-Brasiliana di Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG), and Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).Hematology, Transfusion and Cell Therapy publishes original articles, review articles and case reports covering various areas in the field of hematology and hemotherapy.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Erich De PaulaPublisher website
Editorial board by country: none in mainland China; most named Brazil 55, United States 10, Italy 6, Spain 3, Germany 2 (80 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hemoglobinopathies and Related DisordersMedicine8.9%
- Acute Myeloid Leukemia ResearchMedicine8.1%
- Blood donation and transfusion practicesBusiness, Management and Accounting7.9%
- Chronic Lymphocytic Leukemia ResearchMedicine6.1%
- Acute Lymphoblastic Leukemia researchMedicine5.5%
- Iron Metabolism and DisordersMedicine5.1%
- Healthcare during COVID-19 PandemicComputer Science4.7%
- Chronic Myeloid Leukemia TreatmentsMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.5Publisher website ·
- CiteScore 2026-06
- 2.2LetPub ·
- CiteScore (publisher)
- 2.2Publisher website ·
- SJR 2026-06
- 0.37LetPub ·
- SNIP 2026-06
- 0.62LetPub ·
- h-index
- 31OpenAlex ·
- i10-index
- 189OpenAlex ·
- 2-year mean citedness
- 0.12OpenAlex ·
- Self-citation rate
- 6.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 78LetPub ·
Articles by year OpenAlex count · 11,057 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 177 | 177 | 11 |
| 2025 | 2,397 | 2,397 | 114 |
| 2024 | 2,515 | 2,515 | 479 |
| 2023 | 1,922 | 1,922 | 555 |
| 2022 | 1,370 | 1,370 | 750 |
| 2021 | 1,249 | 1,249 | 1,238 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
182 daysMedian, submission to acceptance · P25–P75 108 days – 280 days
- Acceptance to online
- median 73 days (109 articles)
- Submission to online
- median 258 days
- Sample
- 109 articles with submission and acceptance dates (317 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 30 weeksLetPub ·
- Submission to acceptance
- 166 daysPublisher website ·
- Submission to publication (journal-reported)
- about 30 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY | |
| OpenAlex | USD 0 | — | — | |
| LetPub | No APC | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≥ 1
- Manuscript length
- ≤ 4,000 words
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Cover letter
- Required
- Not considered
- Case reports
Article types accepted11, with length limits
- case reportThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…main text ≤ 1,800 words
- editorialThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…Length not stated
- letterThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…Length not stated
- letter to the editorThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…Length not stated
- letters to the editorure will be considered for publication. Letters to the Editor Maximum of 1000 words (including references) and two illustrations. Images in Climain text ≤ 1,000 words
- literature reviewThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…Length not stated
- original articleThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…main text ≤ 4,000 words · references ≤ 40
- reviewThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…Length not stated
- review articleThe journal publishes the following sections: Original Article, Special Article, Review Article, Updates in the Specialty, Case report, Letter to the Editor, Im…main text ≤ 4,000 words · references ≤ 100
- scientific commentScientific comments Will only be accepted by invitation of the editors.Length not stated
- special articleSpecial ArticleWith the same structure as original articles, this category is used only by the Editor to reclassify Original Articles, depending on their import…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Data availability Data Availability:
Manuscripts must be accompanied by a data availability statement for the data used or generated in the research underlying the texts. Kindly incorporate one of the three options below into the text: URL address of the dataset;Statement that all data are available within the text;Indication that the data must be requested from the corresponding author.
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this) to assign to the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) the copyright in the manuscript and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether…
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Double anonymized peer review Model summary
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Spain
- Language
- English
- ISSN
- 2531-1379
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Hematology Transfusion and Cell Therapy
What CAS zone is Hematology Transfusion and Cell Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hematology Transfusion and Cell Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hematology Transfusion and Cell Therapy?
The journal's website gives an impact factor of 1.5; this is the journal's own figure, as LetPub lists none for it; CiteScore 2.2, h-index 31.
How long does peer review take at Hematology Transfusion and Cell Therapy?
Based on the dates recorded on 109 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 182 days (interquartile range 108–280 days); authors report an average review time of about 30 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Hematology Transfusion and Cell Therapy?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≥ 1; Manuscript length: ≤ 4,000 words; Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Hematology Transfusion and Cell Therapy based?
Of the 80 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Brazil (55), United States (10) and Italy (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Hematology Transfusion and Cell Therapy?
According to LetPub and DOAJ records, Hematology Transfusion and Cell Therapy is indexed in ESCI, Scopus and DOAJ.
Is Hematology Transfusion and Cell Therapy open access, and what is the APC?
Hematology Transfusion and Cell Therapy is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .